A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
Trial details
- Registry ID
- NCT06162286
- Drugs studied
- Moxifloxacin, Omadacycline
TrialRedline tracks 2 clinical trials sponsored by Zai Lab (Hong Kong), Ltd.: 1 Phase 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABPNCT06162286 | Moxifloxacin, Omadacycline | Unknown | 2025-01-01Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque PsoriasisNCT06380907 | ZL-1102 1% w/w gel BID for 16 weeks, ZL-1102 3% w/w gel BID for 16 weeks, ZL-1102 3% w/w gel QD for 16 weeks | Terminated | 2025-12-16Actual |
Names as written in the registry records.
NCT06380907 · Zai Lab (Hong Kong), Ltd.
Before: Estimated. After: Actual.
Before: 250 participants (planned). After: 65 participants (actual).
Before: Estimated. After: Actual.
Before: 28 Feb 2026. After: 16 Dec 2025.
Before: Recruiting. After: Terminated.